Annamycin

The FDA granted fast track designation to annamycin for the treatment of patients with lung metastases from soft tissue sarcoma, according to a press release from the agent’s manufacturer.

The FDA granted orphan drug designation to annamycin for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release.